Hepatitis C is a blood-borne infection caused by the hepatitis C virus (HCV). A chronic infection, which develops in most infected subjects, may lead to liver cirrhosis with ensuing liver dysfunction and liver cancer. About 30% of HIV-positive patients are coifected with HCV. The standard of care in HIV-HCV-coinfected subjects was a combination of pegylated interferon (peg-IFN)-alpha and ribavirin for 48 weeks until few months ago. The eradication of HCV was obtained in 20-55% of cases albeit with significant side effects. Further understanding of host factors that determine the effectiveness of treatment may provide diagnostic tools to distinguish patients who will be cured from those in whom treatment is likely to be futile. The aim of this thesis was to identify biomarkers and some conditions to predict outcome of combination therapy in HIV-HCV-infected patients. The parameters studied included microbial translocation markers as sCD14 and LPS, immune activation profile as CD8+CD38+, CD4+/CD8+ ratio, and in added a HAART intensification with CCR5 inhibitors, maraviroc. We showed that in HIV-HCV patients sCD14 correlates with the severity of liver disease and predicts early response to peg-IFN-apha/ribavirin. Moreover, during anti-HCV therapy there is a higher immune activation by CD8+CD38+ increasing. This data could be a major factor for outcome above all in the first phases of therapy. In conclusion, we evaluated that HAART intensification with maraviroc Per concludere si è valutato come l’intensificazione della terapia HAART con maraviroc could increase T CD4+ recovery and translate in higher probability of sustained virological response in immunological non responder subjects.
Autore:
A. Uglietti
Titolo:
FATTORI PREDITTIVI DI RISPOSTA VIROLOGICA SOSTENUTA IN PAZIENTI CON COINFEZIONE HIV-HCV TRATTATI CON PEG-INTERFERONE E RIBAVIRINA [Tesi di dottorato]
Pubblicazione:
Università degli Studi di Milano, 2014-12-01
Abstract:
Note:
diritti: info:eu-repo/semantics/openAccess
In relazione con info:eu-repo/semantics/altIdentifier/hdl/2434/245615
Autori secondari:
MARCHETTI, GIULIA CARLA
tutor: G. Marchetti ; coordinatore: A. D'Arminio Monforte
D'ARMINIO MONFORTE, ANTONELLA
tutor: G. Marchetti ; coordinatore: A. D'Arminio Monforte
D'ARMINIO MONFORTE, ANTONELLA
Classe MIUR:
Settore MED/17 - - Malattie Infettive
Tesi di dottorato. | Lingua: Italiano. | Paese: | BID: TD16001781
Documenti simili
- PATHOGENESIS OF POOR IMMUNE RECOVERY ON COMBINATION ANTIRETROVIRAL THERAPY (CART): THE ROLE OF THE GASTROINTESTINAL TRACT AND MICROBIAL TRANSLOCATION [Tesi di dottorato] C. Tincati
- Associazione tra calcificazione aortica addominale, patologia cardiovascolare e patologia ossea in una coorte di pazienti con infezione da HIV-1 [Tesi di dottorato] IANNOTTI, NATHALIE
- ROLE OF CART ON GUT MICROBIAL DYSBIOSIS, STUDYING THE GUT/BLOOD MICROBIOTA DURING THE FIRST TWO YEARS OF SUPPRESSIVE CART [Tesi di dottorato] ANCONA, GIUSEPPE
- IL RUOLO DEL PATHWAY SOCS-1/TRAF-6 NELL'INCREMENTO DELL'OSTEOCLASTOGENESI IN PAZIENTI HIV+ IN CART [Tesi di dottorato] CAZZANIGA, FEDERICO ANGELO
- HIV-ASSOCIATED CANCERS: ROLE OF IMMUNE PARAMETERS AND RELATION WITH THE OUTCOME OF CHEMOTHERAPY [Tesi di dottorato] SUARDI, ELISA